Syntegon Group reported strong growth and margin-improvement momentum in the third quarter of 2025, building on a successful first half of the year. The group’s sales in the third quarter increased by 19% compared to the same period of last year, reaching EUR 448 million.

The results were attributed to an organic growth rate of 15%. The main contributor was Syntegon’s Pharma business, which saw a 32% boost in sales.

“Our growth and value-creation strategy is delivering measurable impact and underscores the trust our customers place in Syntegon as their strategic lifecycle partner for mission-critical technologies,” said Torsten Türling, CEO of Syntegon. “With our global footprint and our innovative technologies, we are exceptionally well-positioned to capture the long-term growth opportunities in our customers’ industries.”

Eros Carletti, CFO of Syntegon, said: “Our strong Q3 and year-to-date results underline the financial resilience of our business. Higher volumes in attractive margin segments, combined with seamless project execution and tight cost controls, have enabled us to achieve another quarter of robust profitability. Our solid cash flow further reinforces our financial strength and provides us with the flexibility to continue investing in strategic priorities. We remain committed to driving margin expansion and maintaining a strong financial foundation.”

“With strong growth, consistent margin improvement, and a record-high order backlog, Syntegon remains well positioned to deliver another record year,” the group anticipates.

Photo: Syntegon